Literature DB >> 17032430

Significant morbidity associated with RSV infection in immunosuppressed children following liver transplantation: case report and discussion regarding need of routine prophylaxis.

Samra S Blanchard1, Marla Gerrek, C Siegel, Steven J Czinn.   

Abstract

Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract infection in infants and young children. In immunocompromised children, RSV infection poses a serious health threat with significantly increased and prolonged virus shedding and the development of severe respiratory disease. We report two patients, eight months and 20 months of age, who were admitted with severe RSV infection two months and 10 months post-transplant respectively. Major risk factors for severe infection is the degree of immunosuppression and the age of the patient (<24 months). Based on the significant morbidity associated with RSV infection in these patients, we recommend randomized trials in larger pediatric solid organ transplant centers to evaluate the use of palivizumab prophylaxis is efficacious to prevent morbidity in patients under the age of 24 months, while we emphasize good hygienic practices to prevent RSV nosocomial infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17032430     DOI: 10.1111/j.1399-3046.2006.00583.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  14 in total

1.  What happens when you mix a transplant with respiratory syncytial virus?

Authors:  Joan L Robinson; Danielle Grenier
Journal:  Paediatr Child Health       Date:  2011-01       Impact factor: 2.253

2.  Respiratory Syncytial Virus Prophylaxis in Special Populations: Is it Something Worth Considering in Cystic Fibrosis and Immunosuppression?

Authors:  William A Prescott; David J Hutchinson
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

Review 3.  Monitoring and managing viral infections in pediatric renal transplant recipients.

Authors:  Patrizia Comoli; Fabrizio Ginevri
Journal:  Pediatr Nephrol       Date:  2011-02-26       Impact factor: 3.714

Review 4.  Respiratory viruses other than influenza virus: impact and therapeutic advances.

Authors:  W Garrett Nichols; Angela J Peck Campbell; Michael Boeckh
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

5.  Respiratory syncytial virus NS1 protein colocalizes with mitochondrial antiviral signaling protein MAVS following infection.

Authors:  Sandhya Boyapalle; Terianne Wong; Julio Garay; Michael Teng; Homero San Juan-Vergara; Subhra Mohapatra; Shyam Mohapatra
Journal:  PLoS One       Date:  2012-02-27       Impact factor: 3.240

6.  Clinical outcomes in outpatient respiratory syncytial virus infection in immunocompromised children.

Authors:  Helen Y Chu; Jennifer Chin; Jessica Pollard; Danielle M Zerr; Janet A Englund
Journal:  Influenza Other Respir Viruses       Date:  2016-03-23       Impact factor: 4.380

Review 7.  Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases.

Authors:  Paolo Manzoni; Josep Figueras-Aloy; Eric A F Simões; Paul A Checchia; Brigitte Fauroux; Louis Bont; Bosco Paes; Xavier Carbonell-Estrany
Journal:  Infect Dis Ther       Date:  2017-06-26

Review 8.  Respiratory syncytial virus infections in infants affected by primary immunodeficiency.

Authors:  Marcello Lanari; Silvia Vandini; Maria Grazia Capretti; Tiziana Lazzarotto; Giacomo Faldella
Journal:  J Immunol Res       Date:  2014-06-25       Impact factor: 4.818

Review 9.  The non-immunosuppressive management of childhood nephrotic syndrome.

Authors:  James McCaffrey; Rachel Lennon; Nicholas J A Webb
Journal:  Pediatr Nephrol       Date:  2015-11-10       Impact factor: 3.714

10.  Respiratory viral infections in pediatric solid organ and hematopoietic stem cell transplantation.

Authors:  Defne Arslan; Lara Danziger-Isakov
Journal:  Curr Infect Dis Rep       Date:  2012-12       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.